Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Inflammatory Bowel Diseases

  Free Subscription


Articles published in Eur J Gastroenterol Hepatol

Retrieve available abstracts of 107 articles:
HTML format
Text format



Single Articles


    July 2018
  1. SIMSEK M, Seinen ML, de Boer NKH
    Nodular regenerative hyperplasia in inflammatory bowel disease patients with allopurinol-thiopurine cotherapy.
    Eur J Gastroenterol Hepatol. 2018 Jul 30. doi: 10.1097/MEG.0000000000001218.
    PubMed     Text format    


  2. DE CHAMBRUN GP, Nachury M, Funakoshi N, Gerard R, et al
    Oral vancomycin induces sustained deep remission in adult patients with ulcerative colitis and primary sclerosing cholangitis.
    Eur J Gastroenterol Hepatol. 2018 Jul 26. doi: 10.1097/MEG.0000000000001223.
    PubMed     Text format     Abstract available


  3. NAHON S, Ramtohul T, Paupard T, Belhassan M, et al
    Evolution in clinical presentation of inflammatory bowel disease over time at diagnosis: a multicenter cohort study.
    Eur J Gastroenterol Hepatol. 2018 Jul 12. doi: 10.1097/MEG.0000000000001201.
    PubMed     Text format     Abstract available


  4. GUILCHER K, Fournier N, Schoepfer A, Schibli S, et al
    Change of treatment modalities over the last 10 years in pediatric patients with inflammatory bowel disease in Switzerland.
    Eur J Gastroenterol Hepatol. 2018 Jul 5. doi: 10.1097/MEG.0000000000001197.
    PubMed     Text format     Abstract available


  5. LO B, Julsgaard M, Vester-Andersen MK, Vind I, et al
    Disease activity, steroid use and extraintestinal manifestation are associated with increased disability in patients with inflammatory bowel disease using the inflammatory bowel disease disability index: a cross-sectional multicentre cohort study.
    Eur J Gastroenterol Hepatol. 2018 Jul 3. doi: 10.1097/MEG.0000000000001199.
    PubMed     Text format     Abstract available


    June 2018
  6. REZAPOUR M, Galoosian A, Liu B, Bhuket T, et al
    Clostridium difficile co-infection in inflammatory bowel disease is associated with significantly increased in-hospital mortality.
    Eur J Gastroenterol Hepatol. 2018 Jun 11. doi: 10.1097/MEG.0000000000001185.
    PubMed     Text format     Abstract available


  7. O'CONNELL J, Rowan C, Stack R, Harkin G, et al
    Golimumab effectiveness and safety in clinical practice for moderately active ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2018 Jun 6. doi: 10.1097/MEG.0000000000001177.
    PubMed     Text format     Abstract available


    May 2018
  8. DERIKX LAAP, de Jong ME, Hoentjen F
    Recommendations on rectal surveillance for colorectal cancer after subtotal colectomy in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2018 May 17. doi: 10.1097/MEG.0000000000001171.
    PubMed     Text format     Abstract available


  9. SCHOEPFER A, Vavricka SR, Brungger B, Reich O, et al
    Systematic analysis of annual health resource utilization and costs in hospitalized patients with inflammatory bowel disease in Switzerland.
    Eur J Gastroenterol Hepatol. 2018 May 11. doi: 10.1097/MEG.0000000000001160.
    PubMed     Text format     Abstract available


    April 2018
  10. CHAN W, Lynch N, Bampton P, Chang J, et al
    Entyvio lengthen dose-interval study: lengthening vedolizumab dose interval and the risk of clinical relapse in inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2018 Apr 30. doi: 10.1097/MEG.0000000000001150.
    PubMed     Text format     Abstract available


  11. LAPUMNUAYPOL K, Kanjanahattakij N, Pisarcik D, Thongprayoon C, et al
    Effects of inflammatory bowel disease treatment on the risk of nonalcoholic fatty liver disease: a meta-analysis.
    Eur J Gastroenterol Hepatol. 2018 Apr 24. doi: 10.1097/MEG.0000000000001144.
    PubMed     Text format     Abstract available


    March 2018
  12. HOEKSTRA J, van Roon AHC, Bekkering FC, van Tilburg AJP, et al
    Decision making and outcome of pregnancies in female patients with inflammatory bowel disease: findings from a community-based practice.
    Eur J Gastroenterol Hepatol. 2018 Mar 14. doi: 10.1097/MEG.0000000000001117.
    PubMed     Text format     Abstract available


  13. BINKHORST L, Sobels A, Stuyt R, Westerman EM, et al
    Switching to a infliximab biosimilar: short-term results of clinical monitoring in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2018 Mar 13. doi: 10.1097/MEG.0000000000001113.
    PubMed     Text format     Abstract available


    February 2018
  14. LOBO JL, Garcia-Fuertes JA, Trujillo-Santos J, Merah A, et al
    Anticoagulant therapy for venous thromboembolism in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2018 Feb 16. doi: 10.1097/MEG.0000000000001084.
    PubMed     Text format     Abstract available


  15. NOBILE S, Grand RJ, Pappa HM
    Risk factors for low bone mineral density in pediatric inflammatory bowel disease: the positive role of physical activity.
    Eur J Gastroenterol Hepatol. 2018 Feb 12. doi: 10.1097/MEG.0000000000001076.
    PubMed     Text format     Abstract available


  16. AKAR M, Aydin F, Yurci MA, Abay S, et al
    The possible relationship between Campylobacter spp./Arcobacter spp. and patients with ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2018 Feb 9. doi: 10.1097/MEG.0000000000001095.
    PubMed     Text format     Abstract available


  17. NULSEN B, Sands BE, Shah BJ, Ungaro RC, et al
    Practices, attitudes, and knowledge about Crohn's disease and smoking cessation among gastroenterologists.
    Eur J Gastroenterol Hepatol. 2018;30:155-160.
    PubMed     Text format     Abstract available


  18. BROEKMAN MMTJ, Coenen MJH, Wanten GJ, van Marrewijk CJ, et al
    Patients' beliefs about medicine are associated with early thiopurine discontinuation in patients with inflammatory bowel diseases.
    Eur J Gastroenterol Hepatol. 2018;30:167-173.
    PubMed     Text format     Abstract available


    January 2018
  19. GODAT S, Fournier N, Safroneeva E, Juillerat P, et al
    Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort.
    Eur J Gastroenterol Hepatol. 2018 Jan 30. doi: 10.1097/MEG.0000000000001078.
    PubMed     Text format     Abstract available


  20. HERZOG D, Fournier N, Buehr P, Rueger V, et al
    Age at disease onset of inflammatory bowel disease is associated with later extraintestinal manifestations and complications.
    Eur J Gastroenterol Hepatol. 2018 Jan 22. doi: 10.1097/MEG.0000000000001072.
    PubMed     Text format     Abstract available


  21. ALLOCCA M, Gilardi D, Fiorino G, Furfaro F, et al
    Sexual and reproductive issues and inflammatory bowel disease: a neglected topic in men.
    Eur J Gastroenterol Hepatol. 2018 Jan 18. doi: 10.1097/MEG.0000000000001074.
    PubMed     Text format     Abstract available


  22. VAN ERP SJH, van der Have M, Fidder HH, van der Heijde D, et al
    The effect of arthropathies on illness perceptions, coping strategies, outcomes, and their changes over time in patients with inflammatory bowel disease: a 12-month follow-up study.
    Eur J Gastroenterol Hepatol. 2018 Jan 12. doi: 10.1097/MEG.0000000000001066.
    PubMed     Text format     Abstract available


  23. KRAJCOVICOVA A, Kuzma M, Hlavaty T, Hans D, et al
    Decrease of trabecular bone score reflects severity of Crohn's disease: results of a case-control study.
    Eur J Gastroenterol Hepatol. 2018;30:101-106.
    PubMed     Text format     Abstract available


    December 2017
  24. WALLDORF J, Brunne S, Gittinger FS, Michl P, et al
    Family planning in inflammatory bowel disease: childlessness and disease-related concerns among female patients.
    Eur J Gastroenterol Hepatol. 2017 Dec 5. doi: 10.1097/MEG.0000000000001037.
    PubMed     Text format     Abstract available


    November 2017
  25. HOLKO P, Kawalec P, Mossakowska M
    Quality of life related to oral, subcutaneous, and intravenous biologic treatment of inflammatory bowel disease: a time trade-off study.
    Eur J Gastroenterol Hepatol. 2017 Nov 29. doi: 10.1097/MEG.0000000000001031.
    PubMed     Text format     Abstract available


  26. WILLEMZE RA, Bakker T, Pippias M, Ponsioen CY, et al
    beta-Blocker use is associated with a higher relapse risk of inflammatory bowel disease: a Dutch retrospective case-control study.
    Eur J Gastroenterol Hepatol. 2017 Nov 3. doi: 10.1097/MEG.0000000000001016.
    PubMed     Text format     Abstract available


    October 2017
  27. SKUJA V, Derovs A, Pekarska K, Rudzite D, et al
    Gut colonization with extended-spectrum beta-lactamase-producing Enterobacteriaceae may increase disease activity in biologic-naive outpatients with ulcerative colitis: an interim analysis.
    Eur J Gastroenterol Hepatol. 2017 Oct 25. doi: 10.1097/MEG.0000000000000989.
    PubMed     Text format     Abstract available


    September 2017
  28. BATTAT R, Kopylov U, Byer J, Sewitch MJ, et al
    Vitamin B12 deficiency in inflammatory bowel disease: a prospective observational pilot study.
    Eur J Gastroenterol Hepatol. 2017 Sep 25. doi: 10.1097/MEG.0000000000000970.
    PubMed     Text format     Abstract available


  29. ARGUELLES-ARIAS F, Guerra Veloz MF, Perea Amarillo R, Vilches-Arenas A, et al
    Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results.
    Eur J Gastroenterol Hepatol. 2017 Sep 8. doi: 10.1097/MEG.0000000000000953.
    PubMed     Text format     Abstract available


  30. TIMMER A, Stark R, Peplies J, Classen M, et al
    Current health status and medical therapy of patients with pediatric-onset inflammatory bowel disease: a survey-based analysis on 1280 patients aged 10-25 years focusing on differences by age of onset.
    Eur J Gastroenterol Hepatol. 2017 Sep 4. doi: 10.1097/MEG.0000000000000956.
    PubMed     Text format     Abstract available


    August 2017
  31. COUCOUTSI C, Emmanouil G, Goulielmos G, Sfakianaki O, et al
    Prevalence of thiopurine S-methyltransferase gene polymorphisms in patients with inflammatory bowel disease from the island of Crete, Greece.
    Eur J Gastroenterol Hepatol. 2017 Aug 29. doi: 10.1097/MEG.0000000000000947.
    PubMed     Text format     Abstract available


    June 2017
  32. HOEKMAN DR, Zeevenhooven J, D'Haens GR, Benninga MA, et al
    The prevalence of irritable bowel syndrome-type symptoms in inflammatory bowel disease patients in remission.
    Eur J Gastroenterol Hepatol. 2017 Jun 21. doi: 10.1097/MEG.0000000000000921.
    PubMed     Text format     Abstract available


  33. CARDILE S, Candusso M, Papadatou B, Bracci F, et al
    Lack of efficacy of infliximab in the treatment of primary sclerosing cholangitis in inflammatory bowel diseases in childhood.
    Eur J Gastroenterol Hepatol. 2017;29:736.
    PubMed     Text format    


    May 2017
  34. ORTIZO R, Lee SY, Nguyen ET, Jamal MM, et al
    Exposure to oral contraceptives increases the risk for development of inflammatory bowel disease: a meta-analysis of case-controlled and cohort studies.
    Eur J Gastroenterol Hepatol. 2017 May 24. doi: 10.1097/MEG.0000000000000915.
    PubMed     Text format     Abstract available


  35. RINAWI F, Assa A, Eliakim R, Mozer Glassberg Y, et al
    Predictors of pouchitis after ileal pouch-anal anastomosis in pediatric-onset ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2017 May 24. doi: 10.1097/MEG.0000000000000914.
    PubMed     Text format     Abstract available


  36. BAHLER C, Schoepfer AM, Vavricka SR, Brungger B, et al
    Chronic comorbidities associated with inflammatory bowel disease: prevalence and impact on healthcare costs in Switzerland.
    Eur J Gastroenterol Hepatol. 2017 May 3. doi: 10.1097/MEG.0000000000000891.
    PubMed     Text format     Abstract available


  37. WARDLE RA, Wardle AJ, Charadva C, Ghosh S, et al
    Literature review: impacts of socioeconomic status on the risk of inflammatory bowel disease and its outcomes.
    Eur J Gastroenterol Hepatol. 2017 May 3. doi: 10.1097/MEG.0000000000000899.
    PubMed     Text format     Abstract available


  38. HERZOG D, Fournier N, Buehr P, Rueger V, et al
    Prevalence of intestinal complications in inflammatory bowel disease: a comparison between paediatric-onset and adult-onset patients.
    Eur J Gastroenterol Hepatol. 2017 May 3. doi: 10.1097/MEG.0000000000000896.
    PubMed     Text format     Abstract available


  39. SLONIM-NEVO V, Sarid O, Friger M, Schwartz D, et al
    Effect of threatening life experiences and adverse family relations in ulcerative colitis: analysis using structural equation modeling and comparison with Crohn's disease.
    Eur J Gastroenterol Hepatol. 2017;29:577-586.
    PubMed     Text format     Abstract available


  40. CHEN D, Luo S, Ben Q, Lu L, et al
    Prevalence of hepatitis B and C and factors for infection and nonimmune in inflammatory bowel disease patients in China.
    Eur J Gastroenterol Hepatol. 2017;29:509-515.
    PubMed     Text format     Abstract available


  41. GOTTGENS KW, Jeuring SF, Sturkenboom R, Romberg-Camps MJ, et al
    Time trends in the epidemiology and outcome of perianal fistulizing Crohn's disease in a population-based cohort.
    Eur J Gastroenterol Hepatol. 2017;29:595-601.
    PubMed     Text format     Abstract available


  42. WICKBOM A, Nyhlin N, Montgomery SM, Bohr J, et al
    Family history, comorbidity, smoking and other risk factors in microscopic colitis: a case-control study.
    Eur J Gastroenterol Hepatol. 2017;29:587-594.
    PubMed     Text format     Abstract available


    April 2017
  43. DRAGASEVIC S, Stankovic B, Milosavljevic T, Sokic-Milutinovic A, et al
    Genetic and environmental factors significant for the presentation and development of inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2017 Apr 27. doi: 10.1097/MEG.0000000000000877.
    PubMed     Text format     Abstract available


    March 2017
  44. VAN DEEN WK, Spiro A, Burak Ozbay A, Skup M, et al
    The impact of value-based healthcare for inflammatory bowel diseases on healthcare utilization: a pilot study.
    Eur J Gastroenterol Hepatol. 2017;29:331-337.
    PubMed     Text format     Abstract available


    February 2017
  45. YERUSHALMY-FELER A, Ron Y, Barnea E, Nachum A, et al
    Adolescent transition clinic in inflammatory bowel disease: quantitative assessment of self-efficacy skills.
    Eur J Gastroenterol Hepatol. 2017 Feb 22. doi: 10.1097/MEG.0000000000000864.
    PubMed     Text format     Abstract available


  46. TRIANTAFYLLOU K, Gkolfakis P, Viazis N, Tsibouris P, et al
    A 13-year time trend analysis of 3724 small bowel video capsule endoscopies and a forecast model during the financial crisis in Greece.
    Eur J Gastroenterol Hepatol. 2017;29:185-191.
    PubMed     Text format     Abstract available


  47. DURICOVA D, Fumery M, Annese V, Lakatos PL, et al
    The natural history of Crohn's disease in children: a review of population-based studies.
    Eur J Gastroenterol Hepatol. 2017;29:125-134.
    PubMed     Text format     Abstract available


    January 2017
  48. CHEN D, Luo S, Ben Q, Lu L, et al
    Prevalence of hepatitis B and C and factors for infection and nonimmune in inflammatory bowel disease patients in China.
    Eur J Gastroenterol Hepatol. 2017 Jan 21. doi: 10.1097/MEG.0000000000000838.
    PubMed     Text format     Abstract available


  49. COENEN S, Weyts E, Vermeire S, Ferrante M, et al
    Effects of introduction of an inflammatory bowel disease nurse position on the quality of delivered care.
    Eur J Gastroenterol Hepatol. 2017 Jan 21. doi: 10.1097/MEG.0000000000000839.
    PubMed     Text format     Abstract available


  50. SLONIM-NEVO V, Sarid O, Friger M, Schwartz D, et al
    Effect of threatening life experiences and adverse family relations in ulcerative colitis: analysis using structural equation modeling and comparison with Crohn's disease.
    Eur J Gastroenterol Hepatol. 2017 Jan 4. doi: 10.1097/MEG.0000000000000826.
    PubMed     Text format     Abstract available


    December 2016
  51. VAN ERP SJ, Verheul MK, Levarht EW, van der Reijden JJ, et al
    Absence of serological rheumatoid arthritis biomarkers in inflammatory bowel disease patients with arthropathies.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  52. ROSSI RE, Whyand T, Murray CD, Hamilton MI, et al
    The role of dietary supplements in inflammatory bowel disease: a systematic review.
    Eur J Gastroenterol Hepatol. 2016;28:1357-1364.
    PubMed     Text format     Abstract available


    November 2016
  53. VAN GENNEP S, Sahami S, Buskens CJ, van den Brink GR, et al
    Comparison of health-related quality of life and disability in ulcerative colitis patients following restorative proctocolectomy with ileal pouch-anal anastomosis versus anti-tumor necrosis factor therapy.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  54. ZEITZ J, Bissig M, Barthel C, Biedermann L, et al
    Patients' views on fecal microbiota transplantation: an acceptable therapeutic option in inflammatory bowel disease?
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  55. FALT P, Smajstrla V, Fojtik P, Hill M, et al
    Carbon dioxide insufflation during colonoscopy in inflammatory bowel disease patients: a double-blind, randomized, single-center trial.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


    October 2016
  56. GOYAL H, Singla U, Gupta U, May E, et al
    Role of cannabis in digestive disorders.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  57. TAKS M, Pijls PA, Derijks LJ, Ten Broeke R, et al
    The effect of implementation of a treatment algorithm for infliximab on remission rates and drug costs in inflammatory bowel disease patients.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  58. JOHNSEN KM, Goll R, Hansen V, Olsen T, et al
    Repeated intensified infliximab induction - results from an 11-year prospective study of ulcerative colitis using a novel treatment algorithm.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


    September 2016
  59. FRAGA M, Fournier N, Safroneeva E, Pittet V, et al
    Primary sclerosing cholangitis in the Swiss Inflammatory Bowel Disease Cohort Study: prevalence, risk factors, and long-term follow-up.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  60. WAUTERS L, Billiet T, Papamichael K, Ballet V, et al
    Incidence of renal cell carcinoma in inflammatory bowel disease patients with and without anti-TNF treatment.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  61. ARDESIA M, Costantino G, Fries W
    Lower response to the hepatitis B vaccine in future inflammatory bowel disease patients.
    Eur J Gastroenterol Hepatol. 2016;28:1101-2.
    PubMed     Text format    


    August 2016
  62. VEERAPPAN SG, Healy M, Walsh B, O'Morain CA, et al
    A 1-year prospective study of the effect of infliximab on bone metabolism in inflammatory bowel disease patients.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  63. CAMPOS S, Portela F, Sousa P, Sofia C, et al
    Inflammatory bowel disease: adherence to immunomodulators in a biological therapy era.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  64. BONTA J, Zeitz J, Frei P, Biedermann L, et al
    Cytomegalovirus disease in inflammatory bowel disease: epidemiology and disease characteristics in a large single-centre experience.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


    July 2016
  65. OXELMARK L, Lindberg A, Lofberg R, Sternby B, et al
    Use of complementary and alternative medicine in Swedish patients with inflammatory bowel disease: a controlled study.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  66. SOARES JB, Pereira R, Costa JM, Arroja B, et al
    The Inflammatory Bowel Disease-Disability Index: validation of the Portuguese version according to the COSMIN checklist.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  67. NIV Y
    Mucin gene expression in the intestine of ulcerative colitis patients: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


    June 2016
  68. DE BOER AG, Bennebroek Evertsz' F, Stokkers PC, Bockting CL, et al
    Employment status, difficulties at work and quality of life in inflammatory bowel disease patients.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  69. CARPIO D, Lopez-Sanroman A, Calvet X, Romero C, et al
    Perception of disease burden and treatment satisfaction in patients with ulcerative colitis from outpatient clinics in Spain: UC-LIFE survey.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  70. DE GROOF EJ, Rossen NG, van Rhijn BD, Karregat EP, et al
    Burden of disease and increasing prevalence of inflammatory bowel disease in a population-based cohort in the Netherlands.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  71. DUJARDIN RW, Meijer B, de Boer NK, D'Haens GR, et al
    Usefulness of mean corpuscular volume as a surrogate marker for monitoring thiopurine treatment in inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


    April 2016
  72. ZHENG HH, Jiang XL
    Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis of 16 observational studies.
    Eur J Gastroenterol Hepatol. 2016;28:383-90.
    PubMed     Text format     Abstract available


  73. LEE YJ, Hwang EH, Park JH, Shin JH, et al
    NUDT15 variant is the most common variant associated with thiopurine-induced early leukopenia and alopecia in Korean pediatric patients with Crohn's disease.
    Eur J Gastroenterol Hepatol. 2016;28:475-8.
    PubMed     Text format     Abstract available


    March 2016
  74. PARISI I, O'Beirne J, Rossi RE, Tsochatzis E, et al
    Elevated liver enzymes in inflammatory bowel disease: the role and safety of infliximab.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  75. TERZOUDIS S, Malliaraki N, Damilakis J, Dimitriadou DA, et al
    Chemerin, visfatin, and vaspin serum levels in relation to bone mineral density in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  76. MADIRRALA V, Rooney P, Heath RM, Campbell F, et al
    Short article: Successful faecal coliform sensitivity-based oral ertapenem therapy for chronic antibiotic-refractory pouchitis: a case series.
    Eur J Gastroenterol Hepatol. 2016;28:277-80.
    PubMed     Text format     Abstract available


  77. BOND A, Asher R, Jackson R, Sager K, et al
    Comparative analysis of the influence of clinical factors including BMI on adalimumab and infliximab trough levels.
    Eur J Gastroenterol Hepatol. 2016;28:271-6.
    PubMed     Text format     Abstract available


    February 2016
  78. BODELIER AG, Pierik MJ, Lenaerts K, de Boer E, et al
    Plasma intestinal fatty acid-binding protein fails to predict endoscopic disease activity in inflammatory bowel disease patients.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  79. WASZCZUK E, Waszczuk KM, Mulak A, Paradowski L, et al
    Inadequate seroprotection against hepatitis B virus and one detected case of hepatitis C virus infection among patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  80. KUCHARSKI M, Karczewski J, Mankowska-Wierzbicka D, Karmelita-Katulska K, et al
    Applicability of endoscopic indices in the determination of disease activity in patients with ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  81. FRANCESCHET I, Cazzagon N, Del Ross T, D'Inca R, et al
    Primary sclerosing cholangitis associated with inflammatory bowel disease: an observational study in a Southern Europe population focusing on new therapeutic options.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  82. GUT G, Ben-Tov A, Lahad A, Soferman R, et al
    Pulmonary functions in children with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  83. KUIN S, Stolte SB, van den Brink GR, Ponsioen CY, et al
    Short article: Remicade infusions at home: an alternative setting of infliximab therapy for patients with Crohn's disease.
    Eur J Gastroenterol Hepatol. 2016;28:222-5.
    PubMed     Text format     Abstract available


    January 2016
  84. THORNE K, Alrubaiy L, Akbari A, Samuel DG, et al
    Colectomy rates in patients with ulcerative colitis following treatment with infliximab or ciclosporin: a systematic literature review.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  85. COENEN S, Weyts E, Ballet V, Noman M, et al
    Identifying predictors of low adherence in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  86. WAHID AM, Devarajan K, Ross A, Zilbauer M, et al
    Paediatric gastrointestinal endoscopy: a qualitative study.
    Eur J Gastroenterol Hepatol. 2016;28:25-9.
    PubMed     Text format     Abstract available


    December 2015
  87. WOJTOWICZ AA, Plevinsky JM, Poulopoulos N, Schurman JV, et al
    Examining predictors of healthcare utilization in youth with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2015.
    PubMed     Text format     Abstract available


  88. ROSSI RE, Conte D, Massironi S
    Primary sclerosing cholangitis associated with inflammatory bowel disease: an update.
    Eur J Gastroenterol Hepatol. 2015.
    PubMed     Text format     Abstract available


    November 2015
  89. HUSSEY M, Mc Garrigle R, Kennedy U, Holleran G, et al
    Long-term assessment of clinical response to adalimumab therapy in refractory ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2015.
    PubMed     Text format     Abstract available


  90. DIBLEY L, Norton C, Cotterill N, Bassett P, et al
    Development and initial validation of a disease-specific bowel continence questionnaire for inflammatory bowel disease patients: the ICIQ-IBD.
    Eur J Gastroenterol Hepatol. 2015.
    PubMed     Text format     Abstract available


  91. LEE SY, Jamal MM, Nguyen ET, Bechtold ML, et al
    Does exposure to isotretinoin increase the risk for the development of inflammatory bowel disease? A meta-analysis.
    Eur J Gastroenterol Hepatol. 2015.
    PubMed     Text format     Abstract available


    October 2015
  92. BOLLEN L, Vande Casteele N, Ballet V, van Assche G, et al
    Thromboembolism as an important complication of inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2015.
    PubMed     Text format     Abstract available


  93. SOARES JB, Nogueira MC, Fernandes D, Goncalves BM, et al
    Validation of the Portuguese version of a questionnaire to measure Quality of Care Through the Eyes of Patients with Inflammatory Bowel Disease (QUOTE-IBD).
    Eur J Gastroenterol Hepatol. 2015.
    PubMed     Text format     Abstract available


    September 2015
  94. VOLONAKI E, Mutalib M, Kiparissi F, Shah N, et al
    Adalimumab as a second-line biological therapy in children with refractory ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2015.
    PubMed     Text format     Abstract available


    August 2015
  95. SCAIOLI E, Scagliarini M, Cardamone C, Liverani E, et al
    Clinical application of faecal calprotectin in ulcerative colitis patients.
    Eur J Gastroenterol Hepatol. 2015.
    PubMed     Text format     Abstract available


  96. BELLE A, Baumann C, Bigard MA, Zallot C, et al
    Impact of immunosuppressive therapy on hepatitis B vaccination in inflammatory bowel diseases.
    Eur J Gastroenterol Hepatol. 2015;27:877-81.
    PubMed     Text format     Abstract available


    July 2015
  97. FRELING E, Peyrin-Biroulet L, Poreaux C, Morali A, et al
    IgE antibodies and skin tests in immediate hypersensitivity reactions to infliximab in inflammatory bowel disease: impact on infliximab retreatment.
    Eur J Gastroenterol Hepatol. 2015.
    PubMed     Text format     Abstract available


    June 2015
  98. CARPIO D, Barreiro-de Acosta M, Echarri A, Pereira S, et al
    Influence of urban/rural and coastal/inland environment on the prevalence, phenotype, and clinical course of inflammatory bowel disease patients from northwest of Spain: a cross-sectional study.
    Eur J Gastroenterol Hepatol. 2015.
    PubMed     Text format     Abstract available


    May 2015
  99. SOARES JB, Marinho AS, Fernandes D, Moreira Goncalves B, et al
    Assessing overall patient satisfaction in inflammatory bowel disease using structural equation modeling.
    Eur J Gastroenterol Hepatol. 2015.
    PubMed     Text format     Abstract available


    April 2015
  100. VIAZIS N, Koukouratos T, Anastasiou J, Giakoumis M, et al
    Azathioprine discontinuation earlier than 6 months in Crohn's disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation.
    Eur J Gastroenterol Hepatol. 2015;27:436-41.
    PubMed     Text format     Abstract available


  101. ECHARRI A, Ollero V, Barreiro-de Acosta M, Fernandez-Villaverde A, et al
    Clinical, biological, and endoscopic responses to adalimumab in antitumor necrosis factor-naive Crohn's disease: predictors of efficacy in clinical practice.
    Eur J Gastroenterol Hepatol. 2015;27:430-5.
    PubMed     Text format     Abstract available


    March 2015
  102. NGUYEN DL, Nguyen ET, Bechtold ML
    Outcomes of initial medical compared with surgical strategies in the management of intra-abdominal abscesses in patients with Crohn's disease: a meta-analysis.
    Eur J Gastroenterol Hepatol. 2015;27:235-41.
    PubMed     Text format     Abstract available


    February 2015
  103. PELLINO G, Sciaudone G, Selvaggi F, Riegler G, et al
    Delayed diagnosis is influenced by the clinical pattern of Crohn's disease and affects treatment outcomes and quality of life in the long term: a cross-sectional study of 361 patients in Southern Italy.
    Eur J Gastroenterol Hepatol. 2015;27:175-81.
    PubMed     Text format     Abstract available


    January 2015
  104. AGGARWAL D, Limdi JK
    Anti-TNF therapy is associated with a reduction in radiation exposure in patients with Crohn's disease.
    Eur J Gastroenterol Hepatol. 2015;27:13-9.
    PubMed     Text format     Abstract available


    December 2014
  105. PICHE T, Pishvaie D, Tirouvaziam D, Filippi J, et al
    Osteopathy decreases the severity of IBS-like symptoms associated with Crohn's disease in patients in remission.
    Eur J Gastroenterol Hepatol. 2014;26:1392-8.
    PubMed     Text format     Abstract available


    October 2014
  106. NGUYEN DL, Solaimani P, Nguyen ET, Jamal MM, et al
    Antitumor necrosis factor alpha is more effective than conventional medical therapy for the prevention of postoperative recurrence of Crohn's disease: a meta-analysis.
    Eur J Gastroenterol Hepatol. 2014;26:1152-9.
    PubMed     Text format     Abstract available


  107. MACONI G, Lombardini M, Furfaro F, Bezzio C, et al
    Long-term outcome of inflammatory bowel diseases with cytomegalovirus colitis: effect of antiviral treatment.
    Eur J Gastroenterol Hepatol. 2014;26:1146-51.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: